Revolutionizing Alzheimer's Detection: Immune-Related Gene Biomarkers as Non-Invasive Predictors.

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Early and non-invasive detection of Alzheimer's disease (AD) remains a significant challenge.
• Immune system dysfunction is increasingly recognized as a key factor in AD pathogenesis.
• Developing specific biomarkers requires understanding the molecular basis of the disease.

Purpose of the Study:

• To identify novel, non-invasive biomarkers for early Alzheimer's disease detection.
• To investigate the role of immune system dysfunction in AD development.
• To validate the diagnostic capability of candidate genes in AD patients.

Main Methods:

• Microarray analysis and weighted gene co-expression network analysis (WGCNA) to identify differentially expressed genes (DEGs).
• Functional enrichment analysis and cross-referencing with immune-related genes from ImmPort.
• RT-PCR validation of candidate gene expression and diagnostic accuracy assessment in AD patients.

Main Results:

• Identified 269 DEGs in the blood of AD patients.
• The 'blue' module from WGCNA, primarily involved in immune response, was selected for further analysis.
• Confirmed anomalous expression of IL17C, TEK, and CCL4 in AD patients, achieving 80.2% diagnostic accuracy with a biomarker panel.

Conclusions:

• A biomarker panel comprising IL17C, TEK, and CCL4 demonstrates high precision for Alzheimer's disease detection.
• This panel is based on the immunological response in AD, offering a potential non-invasive diagnostic strategy.
• Further research into immune-related biomarkers could significantly advance early AD diagnosis and treatment.